Primary outcome
What NCT05813912 measured first
| Insulin Icodec + Semaglutiden=91 |
|---|
| -1.23(0.86) |
Phase 3 · Semaglutide
NCT05813912 trial results
Protocol Title: A Single Arm Study Investigating the Glycaemic Control and Safety of Adding Semaglutide to Insulin Icodec in Participants With Type 2 Diabetes Qualifying for Treatment Intensification Short Title: A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
- Participants
- 148
- Status
- completed
- Completed
- 2025-05-16
- Sponsor
- Novo Nordisk A/S
As posted on ClinicalTrials.gov (NCT05813912), updated at source Jun 3, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in NCT05813912
Percent of participants affected, Week 0 to week 57. The most common events the registry lists.
| Event | Icodec: Run-in Period | Insulin Icodec + Semaglutide: Treatment Period |
|---|---|---|
| Any serious event | 4.7% | 3.2% |
| Nausea | 0% | 19.1% |
| Vomiting | 0% | 8.5% |
| Upper respiratory tract infection | 4.1% | 7.4% |
| Decreased appetite | 0% | 6.4% |
| Dyspepsia | 0% | 6.4% |
| Diabetic Retinopathy | 5.4% | 0% |
| Hyperkalaemia | 0% | 5.3% |
Secondary outcomes
What else it measured
| Insulin Icodec + Semaglutiden=82 |
|---|
| -1.69(2.42) |
| Insulin Icodec + Semaglutiden=71 |
|---|
| -1.27(2.17) |
| Insulin Icodec + Semaglutiden=90 |
|---|
| -1.29(2.24) |
| Insulin Icodec + Semaglutiden=94 |
|---|
| 0 |
| Insulin Icodec + Semaglutiden=94 |
|---|
| 13 |
| Insulin Icodec + Semaglutiden=94 |
|---|
| 13 |
| Insulin Icodec + Semaglutiden=92 |
|---|
| -3.85(3.98) |
| Insulin Icodec + Semaglutiden=49 |
|---|
| 0.76(0.72 to 0.81) |
The trial
How NCT05813912 was run
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes. Participants will get the medicine insulin icodec once a week in the first part of the study (run-in period-26 weeks). Participants will only enter the second part of the study if the blood sugar levels have not reduced to normal. If blood sugar levels are normal after the first 26 weeks, participants will continue in a 5-week follow up period. In the second part of the study (intensification period-26 weeks), participants will get both insulin icodec and semaglutide once weekly after which they will continue in a 5-week follow up period. Participants will have to inject the study medicines once a week on the same day of the week in a skin fold in the thigh, upper arm or stomach. The study will last for about 13 months. Participants will get a blood glucose meter to check blood sugar levels. In addition, participants will be asked to enter blood sugar levels in the study phone. In addition, Participants will be asked to enter selected few blood sugar values (three times during the study) in a paper diary that will be provided to participants. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
- Insulin Icodec + Semaglutide: Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.
Who could join the trial
Inclusion Criteria: * Diagnosed with type 2 diabetes (T2D) greater than or equal to (\>=) 180 days prior to the day of screening * HbA1c from 7.5%-10.5% (58-91 millimoles per mole \[mmol/mol\]) (both inclusive) * Treated with once daily or twice daily basal insulin (minimum of 0.25 international units per kilograms per day (IU/kg/day) or 20 IU/day) without concomitant glucagon-like peptide-1 receptor agonists (GLP-1 RA) \>= 90 days prior to the day of screening with or without any of the following antidiabetic drugs/regimens with stable doses \>= 90 days prior to screening: metformin, sulfonylureas, meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose Cotransporter-2 (SGLT2) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors. Oral combination products (for the allowed individual oral anti-diabetic drugs) Exclusion Criteria: * Presence or history of pancreatitis (acute or chronic) within 180 days before screening * Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening and between screening and initiation * Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening * Planned coronary, carotid or peripheral artery revascularization * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and initiation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Published papers
Papers from NCT05813912
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.